U.S. court weighs whether to let Actavis drop Alzheimer's drug

April 13, 2015 6:42 PM

19 0

NEW YORK, April 13 (Reuters) - Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer's drug in favor of a pricier extended-release version, a move that New York's attorney general has said would suppress generic competition.

A three-judge panel of the 2nd U.S. Circuit Court of Appeals peppered attorneys for Actavis and for the attorney general with questions, although the judges gave no clear indication of how they would rule.

Read more

To category page